Pharmacological investigations of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370). 7. Pharmacological comparison with standard anti-inflammatory drugs.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use* / Q000633:toxicity; D001593:Benzyl Compounds / Q000627:therapeutic use; D004487:Edema / Q000188:drug therapy; D005260:Female; D005334:Fever / Q000188:drug therapy; D005439:Flufenamic Acid / Q000627:therapeutic use; D007213:Indomethacin / Q000627:therapeutic use; D007928:Lethal Dose 50; D008297:Male; D008528:Mefenamic Acid / Q000627:therapeutic use; D008744:Methylamines / Q000627:therapeutic use; D051379:Mice; D009281:Naphthalenes / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy; D010437:Peptic Ulcer / Q000139:chemically induced; D010653:Phenylbutazone / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use* / Q000633:toxicity; D051381:Rats; D012459:Salicylates / Q000627:therapeutic use; D013729:Terpenes / Q000627:therapeutic use* / Q000633:toxicity; D014528:Uricosuric Agents / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D001593:Benzyl Compounds; D008744:Methylamines; D009281:Naphthalenes; D011720:Pyrazoles; D012459:Salicylates; D013729:Terpenes; D014528:Uricosuric Agents; D008528:Mefenamic Acid; D005439:Flufenamic Acid; D010653:Phenylbutazone; D007213:Indomethacin